The global Hemophilia Market size is estimated to grow to USD 10.95 Billion in 2022 to USD 16.06 billion by 2030. This market is witnessing a healthy CAGR of 4.9% from 2023 - 2030. The increasing predominance of hemophilia and new products and medication launches for the treatment of hemophilia are majorly driving the growth of the industry.
Industry Overview:
Hemophilia is a hereditary disease in which blood does not coagulate due to insufficient determinants of coagulation. This causes unknown bleeding, pain, swelling and tension in the joints, urine and stool blood, and nosebleeds. Hemophilia management includes quality medical care provided by doctors and nurses who have a comprehensive understanding of the illnesses that help hemophiliacs prevent certain serious complications increase. Often, the best treatment option is the Comprehensive Hemophilia Treatment Center (HTC). Hemophoresis refers to blood convection or flushing of tissues. Desmopressin increases the levels of endogenous factor VIII of hemophilia A.
The large fluctuations between individuals in response to desmopressin are spectacular. Based on expert judgment, prevention with SHL-FVIII concentrate is the standard treatment for patients with severe hemophilia A and may also be considered for certain patients with moderate disease. Hemophilia is primarily a hereditary disorder that interferes with the body's ability to form blood clots, a process required to stop bleeding. Hemophilia occurs in severe, moderate, and mild forms (depending on plasma clotting factor activity levels).
According to a report by the World Federation of Hemophilia in October 2021, men are more prevalent than women because of the sexual association of this condition. Hemophilia occurs worldwide and in all racial groups. According to the Global Hemophilia Federation Global Report published in October 2021, 165,379 patients with hemophilia A, 33,076 patients with hemophilia B, and 11,159 patients with unknown types of hemophilia worldwide. 209,614 people, including humans, have been diagnosed with hemophilia. Such a tremendous prevalence of hemophilia around the world leads to increased adoption of treatments for hemophilia and drives the market growth
Individuals with chronic medical conditions such as hemophilia are susceptible to infections and need to take special precautions to minimize the risk of contracting COVID19, so COVID19 Global outbreaks are estimated to impact the market. In addition, according to an August 2020 study entitled "The Impact of the Covid19 Pandemic on the Prevention of Hemophilia in Children: The Experience of the Hemophilia Treatment Center in West Bengal, India," published in the Journal of Dental and Medical Sciences. The average annual bleeding rate was 2.4 before the lockdown but increased significantly to 8.2 during the lockdown in children who received regular prevention. Of the various reasons they did not visit the hemophilia treatment center, the most important reasons were the lack of transportation (97.5%), the fear of being infected with the coronavirus (95%), and The high cost of alternative transportation (90%). This slowed market growth during the pandemic.
Specific factors driving market growth include increased prevalence of hemophilia, favorable government initiatives, and increased research and progress aimed at developing new therapies.
The increasing predominance of Hemophilia is estimated to drive the growth of the market
Hemophoresis indicates the convection of blood or flushing of tissues. According to the Centers for Disease Control and Prevention (CDC), hemophilia is usually a "hereditary bleeding disorder" in which blood does not coagulate properly. Further CDC updates indicate that this can lead to instinctive bleeding and injuries and post-surgery bleeding, where the blood contains several proteins called coagulation factors that stop bleeding. Patients with hemophilia have reduced levels of either factor VIII (8) or factor IX (9). The severity of hemophilia experienced by a person depends on the number of factors in the blood. The lower the amount of factor, the more likely it is to bleed, which can lead to serious health problems.
New products and medication launches for the treatment of hemophilia are also driving the growth of the market
Hemophoresis is applied to blood convection or flushing of tissues. In January 2022, Biomarin announced the results of a phase III trial using the gene therapy valoctocogener oxaparvovec for severe hemophilia A.
Accessibility to the treatment and the high cost of the treatment is also hampering the growth of the market
Despite advances in the treatment of hemophilia A, there are still administrative disadvantages and treatment costs are rising rapidly. The establishment of inhibitors, the relatively short half-life of molecules that must be infused frequently to maintain active concentrations, and the high cost of replacement therapy pose challenges for clinicians and third-party payers. The challenge in dealing with severe hemophilia A is the establishment of inhibitors. Once this inhibitor is established, administration requires induction of immune regulation and tolerance, which can be complex and costly. Treatment guidelines for establishing inhibitors are inadequate, and there are data to guide clinical management decisions. An additional challenge in the administration of hemophilia A is the individual patient variation in pharmacokinetic response to recombinant factors and the need for frequent dosing. These make treatment planning for individual patients very difficult. Therefore, these issues are hampering the growth of the hemophilia management market.
REPORT METRIC |
DETAILS |
|
Market Size Available |
2022 - 2030 |
|
Base Year |
2022 |
|
Forecast Period |
2023 - 2030 |
|
CAGR |
4.9% |
|
Segments Covered |
By Type, Application, Therapy and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
Bayer AG, BioMarin Pharmaceutical, Inc. CSL Behring, Kedrion, Novo Nordisk, Pfizer, Inc., Roche (Chugai Pharmaceutical Co.), Sanofi (Genzyme Corporation), Takeda Pharmaceutical (Shire Plc.).
|
Hemophilia A
Hemophilia B
Hemophilia C
Others
Based on the type, the market is divided into hemophilia types A, B, C, etc. The classification is based on the lack of coagulation factors in a particular patient. It is commonly observed that type A is the most common type and is four times more common than type B hemophilia.
According to statistics published on WebMDLLC in 2019, the prevalence of type A varies from country to country, ranging from 5,414.5 cases per 100,000 men. In addition, about 50.60% of patients suffer from severe hemophilia A, which is associated with severe bleeding symptoms. In addition, most available products are used to treat hemophilia A.
However, Type B is estimated to be the fastest-growing segment during the forecast period due to its strong pipeline products. In addition, Type B accounts for approximately 20% of hemophilia cases worldwide, of which 50% have factor IX levels above 1%.
On-Demand
Prophylaxis
Based on Treatment, The treatment and hemophilia market is divided into prevention and on-demand treatment. On-demand held the largest market share in 2021, and prevention was estimated to be the fastest-growing segment during the forecast period.
Prophylaxis is a regular injection of coagulation factor concentrate, a commonly used and widely accepted treatment among patients suffering from severe hemophilia, and as a result, its growth rate. It can be obtained. The length of this treatment is determined on the severity of the patient's condition. In addition, prophylactic treatment is anticipated to reduce productivity losses and improve quality of life.
Replacement therapy
ITI therapy
Gene therapy
Based on therapy, Treatments available on the market include immune tolerance induction therapy (ITI), replacement therapy, and gene therapy. Replacement therapy is estimated to be the largest segment in 2021, and gene therapy is anticipated to be the fastest-growing segment during the forecast period. Replacement therapy is considered the standard therapy used for treatment and helps to replace the patient's deficient clotting factors. The gene therapy segment is one of the new areas in that it identifies defective DNA bases and restores them functionally. AMT060 is a potential treatment developed by UniQure for the treatment of type B and is in clinical trials. This treatment works by restoring the patient's factor IX production by introducing a functional copy of the factor IX gene into the hepatocytes of type B patients. In addition, various corporate initiatives to develop gene therapy for hemophilia, including Spark Therapeutics Inc. UniQure; BioMarin promotes segment growth.
North America
Europe
Asia-Pacific
Latin America
The Middle East
Africa
Geographically, North America dominated the market and contributed more than 44.4% to the sales share. Increasing prevalence and increasing trends towards preventative treatment are projected to be the first drivers of regional growth. In the United States, the disease is diagnosed in people at a very young age.
However, the Asia Pacific region is estimated to witness the fastest growth during the forecast period. Early diagnosis of the disease in countries such as Japan, India, Indonesia, and Malaysia and increased per capita use of treatments for factor VIII and factor IX deficiencies are decisive factors.
Bayer AG
BioMarin Pharmaceutical, Inc.
CSL Behring
Kedrion
Novo Nordisk
Pfizer, Inc.
Roche (Chugai Pharmaceutical Co.)
Sanofi (Genzyme Corporation)
Takeda Pharmaceutical (Shire Plc.).
Changed follow-up data from the Phase 1/2 Alta research of giroctocogene fitelparvovec, an analytical gene therapy for patients with moderately significant to serious haemophilia A, were announced by Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic pharmaceuticals company. The results of the Alta research in patients with severe haemophilia A were to be presented at the 63rd American Society for Hematology Annual Meeting and Exposition, which will be held electronically and in Atlanta, GA from December 11-14. The oral presentation slides, which included follow-up data for the longest-treated patient up to 195 weeks, were available on Sangamo's website under Events and Presentations in the Investors and Media area.
Successful Trial - In April 2022, Freeline Therapeutics Holdings plc dosed the first patient in its Phase 1/2 B-LIEVE dose-confirmation clinical trial of FLT180a for the treatment of hemophilia B, a debilitating genetic bleeding disorder caused by a deficiency in the clotting factor IX protein.
Medical Trails - At the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders in April 2022, BioMarin Pharmaceutical Inc. presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study, as well as an overall safety update of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe haemophilia A. (EAHAD).
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
